A Protocol Based Treatment for Early and Severe Systemic Sclerosis With (Anti-CD20), Rituximab

NCT00379431•University Hospital, Ghent

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Early and Severe Systemic Sclerosis

Interventions

Administration of rituximab and methylprednisolone

Locations

Belgium

Locations (4)

UCL St. Luc Brussel

Brussels, Belgium

UZ Brussel

Brussels, Belgium

University Hospital Ghent

Ghent, Belgium

UZ Gasthuisberg Leuven

Leuven, Belgium

Key Dates

Start Date

November 27, 2006

Primary Completion Date

February 2, 2009

Completion Date

February 2, 2009

Last Updated

December 20, 2022

Sponsors

Lead Sponsor

University Hospital, Ghent

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 20, 2022Data synced to Clareo: April 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions